EGFR and lung adenocarcinoma: Recent findings from the ADAURA trial have shown that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve DFS duration by approximately 18 months in stage IB lung adenocarcinoma (LADC) patients with EGFR mutations [4].